Gastroenterology Research and Practice / 2017 / Article / Tab 4

Research Article

Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors

Table 4

Risk of disease recurrence according to Cox regression test.

VariableUnivariateMultivariate
HRCI 95%HRCI 95%

Male gender1.0140.3–3.10.98
No syndrome3.0640.4–23.60.282
GI-NET1.8740.6–5.80.276
Grading G26.5782.0–21.80.002ns
Stage IIIB-IV105.3041.0–10,718-10.048105.1542.1–3099.1<0.000001
Low SSTR2A QS2.8860.8–10.60.11
Low IGF-1R QS9.8931.3–76.20.028ns
High p-mTOR QS3.7001.2–11.10.02ns

HR: hazard ratio; CI: confidence interval; ns: not statistically significant; GI-NET: gastrointestinal primary NET (versus pancreatic NET); SSTR2A: somatostatin receptor 2A; IGF-1R: insulin-like growth factor-1 receptor; p-mTOR: phosphorylated mammalian target of rapamycin; QS: quantitative score.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.